Ximbio (the research tools trading arm of Cancer Research Technology Limited), has signed a new agreement with ERS Genomics Limited for a non-exclusive licence to their CRISPR-Cas9 technology. 

Under the licence, Ximbio can develop and commercialise CRISPR-Cas9 cell lines and other non-animal CRISPR-Cas9 research tools for research use only. Ximbio can provide these modified CRISPR-Cas9 cell lines to companies, for internal research use purposes, under a label-use only licence. 

Ximbio’s licencagreement with ERS Genomics Limited provides significant benefits to the life science community who are looking to deposit their own CRISPR-Cas9 research tools with Ximbio and who can now access CRISPR-Cas9 research tools that have been developed by others.  

ERS Genomics Ltd holds an exclusive worldwide licence from Prof. Emmanuelle Charpentier to the foundational intellectual property covering CRISPR-Cas9 for all applications other than use as a human therapeutic. Prof. Emmanuelle Charpentier together with Prof. Jennifer Doudnaisolated the components of the CRISPR-Cas9 system and demonstrated it could be programmed to cut specific sites in isolated DNA. This has led to multiple applications in medicine, agriculture and basic science. As a result, Charpentier and Doudna were awarded the 2020 Nobel prize in Chemistry. A list of the patent rights owned by ERS Genomics Ltd can be found on our website. 

Some of the CRISPR tools already on the Ximbio portfolio include human HEK-ADAM10 cell linepROSA26-Puro-GFP CRISPR vectorHEK293 GRASP65 knockout cell line and U2OS E2F7 KO cell line 

For further information or if you have any queries,

CRISPR-Cas9 stock image